share_log

摩根大通上调目标价至44美元 再鼎医药涨逾23%

智通财经APP ·  Oct 24 21:56  · Ratings

周四,再鼎医药(ZLAB.US)股价大幅高开,随后快速拉高,盘中一度涨超26%,截至发稿,上涨23.02%,报35.602美元。消息面上,再鼎医药在EORTC-新华保险-AACR 2024年研讨会上展示了Zl-1310进行中的1a/10亿研究数据,ZL-1310在复发性广泛期小细胞肺癌(SCLC)患者中,所有测试剂量水平的客观反应率(ORR)为74%。此外,摩根大通将再鼎医药目标价从38美元上调至44美元。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment